Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Completed · Phase 2 · Has a placebo group

Conditions studied: Lupus Membranous Nephropathy

In brief

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).

Key facts

Study ID

NCT03285711

Run by

Gilead Sciences

People needed

9

Starts

2017-10-06

Expected to finish

2020-02-03

Last updated by the study team

2020-05-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University — Palo Alto, California, United States
• University of Florida — Gainesville, Florida, United States
• Emory University School of Medicine — Atlanta, Georgia, United States
• Georgia Nephrology Research Institute — Lawrenceville, Georgia, United States
• University of Michigan — Ann Arbor, Michigan, United States
• University of North Carolina at Chapel Hill / UNC School of Medicine — Chapel Hill, North Carolina, United States
• University of Alabama at Birmingham (UAB) — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.